Integra Therapeutics, a Barcelona, Spain-based company which specializes in gene writing tools, received up to €10.5M from European Commission via the European Innovation Council (EIC) Accelerator program
The company intends to use the funds to launch its first gene therapy to treat a serious pediatric hepatic disease, among other activities.
In parallel, the company will generate FiCAT proof of concept data on its first gene therapy, using systemic administration with non-viral vectors through lipid nanoparticles (LNP) to treat a serious pediatric hepatic disease.
Co-founded by Dr. Marc Güell and Dr. Avencia Sánchez-Mejías, Integra Therapeutics is a biotech company that creates gene writing tools to improve the safety and efficacy of advanced therapies. It was founded in 2020 as a spin-off of the Pompeu Fabra University (UPF) and has secured the backing of international investors (AdBio Partners, Columbus Venture Partners, Invivo Capital, and Takeda Ventures) and organizations in the health and biomedical sector. It earned My Green Lab sustainability certification in 2023.
FinSMEs
17/07/2024